Table 2

Prevalence of patients with a PD-score>0 at joints, perisynovial tissue, entheses or tendons according to clinical remission/MDA criteria

PD-j-score >0
n (%)
PD-perisyn>0
n (%)
PD-MASEI+E>0
n (%)
PD-teno>0
n (%)
MDA
 r (21)16 (76.2)3 (14.3)15 (71.4)4 (19.0)
 a (49)40 (81.6)7 (14.3)28 (57.1)19 (39.6)*
CPDAI-JED
 r (15)10 (66.7)3 (20.0)11 (73.3)2 (13.3)
 a (55)46 (83.6)7 (12.7)32 (58.2)21 (38.9)*
DAPSA
 r (12)7 (58.3)2 (16.7)8 (66.7)1 (8.3)
 a (58)49 (84.5)**8 (13.8)35 (60.3)22 (38.6)**
Boolean's
 r (11)5 (54.5)1 (9.1)8 (72.7)1 (9.1)
 a (59)50 (84.7)**9 (15.3)35 (59.3)22 (37.9)*
rem-phys
 r (33)25 (75.8)3 (9.1)21 (63.6)7 (21.9)
 a (37)31 (83.3)7 (18.9)22 (59.5)16 (43.2)*
  • *p<0.1; **p<0.05 according to Fisher's exact test.

  • a, active disease—the number of patients in remission or with active disease is shown in parenthesis; Boolean's, Boolean's definition of remission; rem-phys, remission as judged by the treating physician; CPDAI-JED, joint, entheses and dactylitis domains of the Composite Psoriatic Disease Activity Index; DAPSA, Disease Activity Index for Psoriatic Arthritis; MDA, minimal disease activity; n, number (percentage in parenthesis); MASEI, Madrid Sonographic Enthesis Index; PD-j-score, power Doppler (PD) score of joints; PD-MASEI-E, sum of entheses with PD-signals; enthesal sites were scanned according to Madrid Sonographic Enthesis Index plus lateral epicondyle; PD-perisyn, PD within peritendinous tissue; PD-teno, sum score of PD-signals related to tenosynovitis; r, remission/MDA.